| Literature DB >> 14962582 |
Sherry L Morissette1, Orn Almarsson, Matthew L Peterson, Julius F Remenar, Michael J Read, Anthony V Lemmo, Steve Ellis, Michael J Cima, Colin R Gardner.
Abstract
The concepts of high-throughput (HT) screening and combinatorial synthesis have been integrated into the pharmaceutical discovery process, but are not yet commonplace in the pharmaceutical development arena. Emerging strategies to speed pharmaceutical development and capture solid form diversity of pharmaceutical substances have resulted in the emergence of HT crystallization technologies. The primary type of diversity often refers to polymorphs, which are different crystal forms of the same chemical composition. However, diverse salt forms, co-crystals, hydrates and solvates are also amenable to study in HT crystallization systems. The impact of form diversity encompasses issues of stability and bioavailability, as well as development considerations such as process definition, formulation design, patent protection and regulatory control. This review highlights the opportunities and challenges of HT crystallization technologies as they apply to pharmaceutical research and development.Mesh：
Substances：
Year: 2004 PMID： 14962582 DOI： 10.1016/j.addr.2003.10.020
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 15.470